16 June 2020: Clinical Research
Knowledge and Awareness of Venous Thromboembolism in Intensive Care Units in Zhejiang Province, China: A Cross-Sectional Survey
Jing Yan AG , Jia Zhou BC , Junhai Zhen BC , Li Li ABEG*DOI: 10.12659/MSM.923378
Med Sci Monit 2020; 26:e923378
Table 2 VTE clinical treatments.
| Total (n=96) | Tertiary hospitals (n=70) | Secondary hospitals (n=26) | |
|---|---|---|---|
| Preferred drugs for thrombolytic therapy | |||
| Urokinase | 20 (20.8%) | 13 (18.6%) | 7 (26.9%) |
| rt-PA | 76 (79.2%) | 57 (81.4%) | 19 (73.1%) |
| Others | 0 | 0 | 0 |
| Preferred drugs for short-term intravenous anticoagulant therapy | |||
| Standard heparin | 6 (6.3%) | 6 (8.6%) | 0 (0%) |
| Low molecular weight heparin | 90 (93.8%) | 64 (91.4%) | 26 (100%) |
| Direct Factor IIa inhibitor | 0 | 0 | 0 |
| Preferred drugs for long-term anticoagulant therapy | |||
| Warfarin | 75 (78.1%) | 53 (75.7%) | 17 (84.6%) |
| Direct Factor Xa inhibitor | 19 (19.8%) | 17 (24.3%) | 2 (7.7%) |
| Direct thrombin inhibitors | 0 | 0 | 0 |
| Rehabilitation or physical function exercise | 15 (15.6%) | 10 (14.3%) | 5 (19.2%) |
| rt-PA – recombinant tissue plasminogen activator. | |||